Company*
(Country; Symbol)

Product

Description

Indication

Status (Date)


AUTOIMMUNE

Abbott
Laboratories

Humira (FDA-approved)

Adalimumab; fully human antibody designed to block TNF-alpha

Psoriatic arthritis and ankylosing spondylitis

Presented data from trials that showed benefit in each indication (6/15)

Amgen
Inc.
(AMGN)

Enbrel (FDA-approved)

Etanercept; anti-tumor necrosis factor-alpha antibody

Rheumatoid arthritis

Two-year data from TEMPO trial showed Enbrel improved clinical remission at two years compared to methotrexate alone (6/10)

Antisense
Therapeutics
Ltd.
(Australia;
ASX:ANP) and
Isis Pharmaceuticals
Inc.
(ISIS)

ATL-1102

Second-generation inhibitor of very late-antigen-4

Multiple sclerosis

Phase I trial showed drug appeared to be well tolerated, and the study produced a dose for Phase II development (6/8)

Arakis Ltd.* (UK)

AD 452

Single-isomer form of a drug marketed in a different indication

Rheumatoid arthritis

Began Phase IIa trial in 96 RA patients to study pharmacokinetics, safety and tolerability of a range of doses (6/8)

Aspreva
Pharmaceuticals
Corp.*

CellCept

Mycophenolate mofetil; an immunosuppressant

Myasthenia gravis

Began Phase III trial that will include 136 patients in five countries to test safety and efficacy (6/7)

Centocor Inc.
(unit of Johnson &
Johnson)

Remicade (FDA-approved)

Infliximab; monoclonal antibody that targets and binds tumor necrosis factor-alpha

Ankylosing spondylitis

ASSERT trial demonstrated that drug improved signs and symptoms of the disease vs. placebo (6/14)

Centocor Inc.
(unit of Johnson
& Johnson)

Remicade (FDA-approved)

Infliximab; monoclonal antibody that targets and binds tumor necrosis factor-alpha

Rheumatoid arthritis

Data from ASPIRE trial showed improved bone erosion scores vs. methotrexate alone in early RA patients (6/11)

Centocor
Inc.
(unit of
Johnson &
Johnson)

Remicade (FDA-approved)

Infliximab; monoclonal antibody that targets and binds tumor necrosis factor-alpha

Psoriatic arthritis

Phase III IMPACT 2 trial showed improvements in both the arthritis and psoriasis associated with PA (6/10)

Genentech Inc. (NYSE:DNA)
and Biogen Idec
Inc.
(BIIB)

Rituxan (FDA-approved)

Rituximab; antibody that binds to the CD20 antigen on the surface of normal and malignant B cells

Rheumatoid arthritis

Published Phase IIa data showed a statistically significant benefit in combination group vs. methotrexate alone (6/16)

Hemispherx
Biopharma Inc.
(AMEX:HEB)

Alferon N

Purified mixture of natural alpha interferons

Multiple sclerosis

Began Phase IIa program to test safety and efficacy in 50 patients who discontinued other treatments (6/14)

Neurogen
Corp.
(NRGN)

NGD 2000-1

Oral C5a antagonist

Rheumatoid arthritis

Phase IIa trial failed to meet its primary endpoint, change in C-reactive protein, but fared better on secondary endpoints (6/15)

CANCER

Advanced Viral
Research Corp.
(OTC BB:ADVR)

AVR118

Peptide-nucleic acid complex with immunomodulatory properties

Cachexia

Phase I/II trial in cancer and AIDS patients showed an increase in weight, strength and fat percentage with all doses (ASCO)

Aesgen Inc.*

Saforis

L-glutamine delivered with company's technology

Oral mucositis in cancer patients

Phase III trial showed significant reduction in severity and duration of condition in patients with breast and other cancers (ASCO)

AEterna Zentaris Inc. (Canada; AEZS) and Keryx Biopharmaceuticals Inc. (KERX)

Perifosine (KRX-0401)

Orally active AKT inhibitor

Advanced solid tumors

Phase I trial demonstrated safety and tolerability, dose-limiting toxicity and evidence of antitumor activity (ASCO)

Agennix Inc.*

--

Oral recombinant human lactoferrin

Metastatic cancers

Data from two Phase I/II trials showed a statistically significant reduction in the average tumor growth rate (ASCO)

Allos Therapeutics
Inc.
(ALTH)

RSR13 (efaproxiral)

Small molecule designed to sensitize hypoxic areas of tumors prior to radiation

Brain metastases

Retrospective Phase III data showed benefit in metastases from non- small-cell lung cancer; presented already-reported positive Phase III REACH trial data (ASCO)

American BioSciences
Inc.
(APPX)

Abraxane

Nanoparticle albuminbound taxane

Advanced breast cancer and other solid tumors

Phase II trial produced a response rate of 15% in advanced breast cancer; Phase I trial showed drug was well tolerated at high doses with weekly dosing (ASCO)

Amgen
Inc.
(AMGN)

Aranesp (FDA- approved)

Darbepoetin alfa, a recombinant erythropoietic protein

Anemia from chemotherapy

Final data from three trials showed Aranesp every two weeks was comparable to weekly epoetin (Procrit); also, three-week dosing achieved target hemoglobin levels; trial showed drug could be useful in anemia in patients not on chemotherapy (ASCO)

Amgen
Inc.
(AMGN )
and Abgenix
Inc.
(ABGX)

Panitumumab (formerly ABX-EGF)

Fully human monoclonal antibody that targets the epidermal growth factor receptor

Metastatic colorectal cancer

Phase II trial demonstrated anti-tumor activity as a single agent in patients who had failed other treatments (ASCO)

Angstrom Pharmaceuticals
Inc.*

A6

Agent that targets the urokinase plasminogen- activator system

Preventing relapse in ovarian cancer

Began Phase II trial to assess safety in 48 to 60 asymptomatic women (6/14)

AnorMed
Inc.
(Canada;
TSE:AOM)

AMD3100

Designed to block receptor that triggers movement of stem cells out of bone marrow

Stem cell transplantation in cancer patients

Phase II trial in 10 multiple myeloma patients showed it helped patients undergo a tandem stem cell transplant procedure (ASCO)

Antigenics Inc.
(AGEN)

Oncophage

Personalized cancer vaccine based on heat-shock protein technology

Metastatic melanoma

Ten of 16 patients with residual melanoma post- surgery experienced disease stabilization (ASCO)

Aphton
Corp.
(APHT)

G17DT

Immunotherapy vaccine designed to induce antibodies that bind to both gastrin 17 and glygastrin 17

Various cancers

Presented Phase III data showing statistically significant survival benefit as monotherapy in advanced pancreatic cancer patients who can't take chemotherapy; also presented Phase II combination studies in other cancers (ASCO)

Ariad
Pharmaceuticals
Inc.
(ARIA)

AP23573

Small molecule designed to inhibit cell-signaling protein mTOR

Advanced solid tumors

Phase I single-agent trials demonstrated antitumor activity in 50% of patients dosed daily and 17% of patients dosed weekly (ASCO); began single-agent Phase II trial in relapsed hematological cancers in up to 200 patients (6/15)

Array
BioPharma
Inc.
(ARRY)

ARRY-142886 (AZD6244)

Selective, ATP non- competitive inhibitor of MEK 1/2

Advanced cancers

Began Phase I trial to evaluate tolerability and pharmacokinetics, as well as indications of biological activity (6/14)

Biogen
Idec Inc.
(BIIB)

Zevalin (FDA- approved)

Ibritumomab tiuxetan; monoclonal antibody targeting CD20 combined with radioisotope

Low-grade follicular lymphoma

Phase II trial showed combination with Rituxan might produce high complete remission rates in previously untreated patients (ASCO); drug produced durable responses in 78 of 211 refractory patients with non- hodgkin's lymphoma (6/14)

Biomira Inc.
(Canada; BIOM)

Theratope

Vaccine combining mimic of cancer antigen sialyl-Tn and carrier molecule KLH

Metastatic breast cancer

Exploratory analysis of Phase III trial showed statistical significance in hormonal therapy subset of women (ASCO)

CancerVax
Corp.
(CNVX)

SAI-EGF

Immunotherapeutic agent targeting the epidermal growth factor receptor

Non-small-cell lung cancer

Phase I/II data showed therapy was well tolerated, resulted in immune responses and may increase survival (ASCO)

CancerVax
Corp.
(CNVX)

Canvaxin

Therapeutic whole-cell vaccine that expresses more than 20 antigens

Stage IV melanoma

Restrospective analysis of Phase II trial in 1,856 patients showed a significant improvement in overall survival (ASCO)

Can-Fite Biopharma Ltd.* (Israel)

CF101

Adenosine 3 receptor agonist

Solid tumors

Began Phase I trial to test safety, tolerability and clinical effects in combination with three different chemotherapy regimens (6/30)

Celgene
Corp.
(CELG)

Thalomid (FDA-approved)

Thalidomide

Multiple myeloma and metastatic melanoma

Phase III trial showed a statistically significant response increase in combination with dexamethasone vs. dexamethasone alone; Phase II trial with melphalan and prednisone also showed benefit; ongoing Phase II data with temozolomide for metastatic melanoma also were presented (ASCO)

Cell Genesys
Inc.
(CEGE)

GVAX

Whole-cell vaccine comprised of tumor cells irradiated and modified to secrete GM-CSF

Acute myelogenous
leukemia and prostate cancer

Presented encouraging follow- up data from Phase II trials in both AML and advanced hormone-refractory prostate cancer (ASCO)

Cell Genesys
Inc.
(CEGE)

CG7870

Oncolytic virus therapy

Metastatic prostate
cancer

Final Phase I/II data showed five of 23 patients (3 of 5 in highest dose groups) had reduced PSA levels (ASCO)

Cell Genesys
Inc.
(CEGE)

GVAX

Whole-cell vaccine comprised of tumor cells irradiated and modified to secrete GM-CSF

Lung cancer

Began Phase II trial in 100 patients with advanced-stage broncho-alveolar carcinoma, the second of two Phase IIs in lung cancer (6/28)

Cell Genesys
Inc.
(CEGE)

GVAX

Whole-cell vaccine comprised of tumor cells irradiated and modified to secrete GM-CSF

Pancreatic cancer

Phase II exploratory trial in 50 inoperable patients showed tolability with cyclophosphamide and trends toward improved outcomes (6/26)

Cell Therapeutics
Inc.
(CTIC)

CT-2106

A polyglutamate camptothecin

Solid tumors

Phase I data showed the drug was well tolerated and lacked certain toxicities typical of camptothecins (ASCO)

Cell Therapeutics
Inc.
(CTIC)

Xyotax

Paclitaxel linked to biodegradable polyglutamate polymer

Non-small-cell lung cancer

Update on Phase III trial showed higher survival rates than in historical controls, thus extending the study (ASCO)

Cell Therapeutics Inc. (CTIC)

Trisenox (FDA- approved)

Arsenic trioxide

Late-stage multiple myeloma

Phase II trial with vitamin C and melphalan produced responses in seven of 13 relapsed patients (6/14)

Cell Therapeutics
Inc.
(CTIC)

Trisenox (FDA- approved)

Arsenic trioxide

Myelodysplasia

Phase II trial in 62 patients demonstrated activity in both low- and high-risk disease (ASCO); Phase II single-agent trial produced a hematologic response rate of 27% (6/10)

Cel-Sci Corp. (AMEX:CVM)

Multikine

Mixture of human cyto- ines designed to stimulate an immune response

Head and neck cancer

Phase II data from 39 patients showed those on drug had more cancer cells killed and a 42% response rate (ASCO)

ChemGenex Therapeutics
Inc.*

Quinamed

Amonafide dihydrochloride; topoisomerase II inhibitor

Solid tumors

Presented positive data from 32-patient study that used genotyping to determine dosing (ASCO)

Chiron
Corp.
(CHIR)

Proleukin

Recombinant form of human interleukin-2

Non-Hodgkin's lymphoma

Began Phase II trial with Rituxan to assess combination in first- time Rituxan patients (ASCO)

Coley Pharmaceutical Group Inc.*

ProMune (CPG 7909)

Toll-like receptor 9 agonist

Advanced non- small-cell lung cancer

More objective tumor responses were seen with ProMune combination than with chemotherapy alone in Phase II trial (ASCO)

Corixa
Corp.
(CRXA)

Bexxar (FDA-approved)

Radiotherapeutic combining tositumomab and iodine-131

Non-Hodgkin's lymphoma

Two trials using Bexxar after chemotherapy produced complete responses in 80% to 83% of patients with advanced follicular B-cell NHL (ASCO)

Cytogen
Corp.
(CYTO)

Quadramet

Samarium-153 lexidron injection; skeletal-targeting radiopharmaceutical

Bone metastases and prostate cancer

Data from three trials showed the agent may work synergistically with other approaches in metastases from various tumors (ASCO); 30- patient study showed survival benefit (p=0.02) in hormone- refractory prostate cancer (6/22)

Cytokinetics
Inc.
(CYTK) and GlaxoSmithKline
plc (UK)

SB-743921

Small-molecule inhibitor of kinesin spindle protein

Advanced solid tumors

Phase I trials showed the agent might be well tolerated in that patient group (ASCO)

Dendreon
Corp.
(DNDN)

APC8024

Immunotherapy; vaccine that targets tumors expressing the HER2/neu marker

Metastatic solid tumors

Phase I trial demonstrated a statistically significant T-cell immune response in patients with HER2/neu-positive cancers (ASCO)

DUSA
Pharmaceuticals
Inc.
(DUSA)

Levulan (FDA- approved)

Photodynamic therapy

High-grade dysplasia within Barrett's esophagus

Began pilot Phase II trial to gather information on new endoscopic light delivery system (6/8)

Exelixis
Inc.
(EXEL)

XL999

Spectrum selective kinase inhibitor, targeting receptor tyrosine kinases

Cancers

Filed IND for Phase I trial to test safety, tolerability, pharmaco-kinetics and biological activity in patients (6/29)

Exelixis
Inc.
(EXEL)

XL119

Becatecarin; small-molecule cancer compound

Bile duct cancer

Began Phase III trial vs. chemotherapy in up to 600 patients to assess survival (6/23)

Exelixis
Inc.
(EXEL)

XL647

Oral compound targeting multiple receptor tyrosine kinases

Solid tumors

Began Phase I trial to evaluate safety, tolerability and pharmaco-kinetics in patients for whom there is no alternative therapy (6/3)

Epimmune
Inc.
(EPMN)

EP-2101

Immunotherapy; multi-pitope vaccine

Cancers

Results from 10 patients in Phase I/II trial showed it was safe and well tolerated, and induced a multi-epitope response (ASCO)

Genaera
Corp.
(GENR)

Squalamine

Anti-angiogenesis agent; vascular endothelial growth factor inhibitor

Non-small-cell lung cancer

Updated Phase IIb data showed drug with chemotherapy was well tolerated and produced a 72% overall response rate (ASCO)

Genentech Inc. (NYSE:DNA)

Avastin (FDA- approved)

Bevacizumab; antibody designed to inhibit vascular endothelial growth factor

Metastatic pancreatic and colorectal cancer

Among presentations was a Phase II trial with gemcitabine showing one-year survival of 54% in pancreatic cancer and a survival benefit in Phase II trial with 5-FU/leucovorin in colorectal cancer (ASCO)

Genentech Inc. (NYSE:DNA) and OSI Pharmaceuticals Inc. (OSIP)

Tarceva and Avastin (FDA- approved)

Erlotinib HCl; small- molecule HER1/EGFR inhibitor; and bevacizumab; antibody designed to inhibit vascular endothelial growth factor

Metastatic renal- cell carcinoma and non-small- cell lung cancer

Phase II trial in metastatic kidney cancer showed 12 of 58 patients had an objective response to the combination and 38 a minor response; clinical benefit also was seen in Phase I/II NSCLC trial; (ASCO)

Genentech Inc. (NYSE:DNA) and OSI Pharmaceuticals Inc. (OSIP)

Tarceva

Erlotinib HCl; small-molecule HER1/EGFR inhibitor

Advanced non-small-cell lung and other cancers

Phase III trial in NSCLC showed a 42.5% improvement in median survival and 41% in one-year survival vs. placebo; Tarceva did not improve on standard chemotherapy in advanced lung cancer (ASCO)

Genentech Inc. (NYSE:DNA) and Biogen Idec Inc. (BIIB)

Rituxan (FDA- approved)

Rituximab; antibody that binds to the CD20 antigen on normal and malignant B cells

Non-Hodgkin's lymphoma

Phase III trial in 824 patients demonstrated a significant improvement in time to treatment failure, the primary endpoint; Phase III maintenance trial with chemotherapy showed significant improvement in progression-free survival (ASCO)

Genentech Inc. (NYSE:DNA)

Herceptin (FDA-approved)

Trastuzumab; monoclonal antibody against HER2/neu protein

HER2-positive metastatic breast cancer

Presented data showing trend of improved survival in study with paclitaxel and carboplatin, and presented 50 other studies of various treatment regimens (ASCO)

Genmab
A/S
(Denmark;
CSE:GEN)

HuMax-CD20

Human antibody that binds to the CD20 antigen

Chronic lymphocytic leukemia

Began Phase I/II dose- escalation trial to measure responses in 32 patients with relapsed or refractory CLL (6/21)

GenVec
Inc.
(GNVC)

TNFerade

Adenovector with TNF- alpha gene and a radiation- responsive promoter

Locally advanced prostate cancer

Presented promising survival data from Phase II trial in combination with standard therapy in unresectable disease (ASCO)

Genzyme
Corp.
(GENZ)

Thyrogen (FDA-approved)

Thyrotropin alfa for injection; a recombinant human thyroid- stimulating hormone

Thyroid tumors

Trial in 63 patients showed agent was as effective for remnant ablation as thyroid hormone withdrawal, with reduced side effects (6/16)

Geron
Corp.
(GERN)

--

Telomerase therapeutic vaccine that uses ex vivo dendritic-cell technology

Metastatic prostate cancer

Phase I/II trial showed 19 of 20 patients generated telomerase-specific cytotoxic T cells, without any side effects (ASCO)

Gloucester Pharmaceuticals
Inc.*

FK228

Depsipeptide; bicyclic peptide, histone deacetylase inhibitor

T-cell lymphomas

Presented encouraging data on tolerability and responses from ongoing Phase II trial (ASCO)

GTx
Inc.
(GTXI)

Acapodene (toremifene citrate)

Small-molecule non- steroidal selective estrogen receptor modulator

Side effects of androgen-deprivation therapy

Phase II trial showed product was well tolerated and reduced bone mineral density better than placebo (ASCO)

GTx
Inc.
(GTXI)

Acapodene (toremifene citrate)

Small-molecule non- steroidal selective estrogen receptor modulator

Prostate cancer

Phase II trial in men demonstrated tolerability and the reduction of disease in those with high-grade prostatic intraepithelial neoplasia (6/2)

Human
Genome
Sciences
Inc.
(HGSI)

HGS-ETR1

Agonistic human mono- clonal antibody to TRAIL receptor-1

Cancers

Phase I trials demonstrated safety and tolerability, as well as biological activity (ASCO)

ILEX
Oncology
Inc.
(ILXO)

Campath (FDA- approved)

Alemtuzumab; humanized monoclonal antibody that binds to CD52 on cell surfaces

B-cell chronic lymphocytic leukemia

Interim safety update was positive from Phase III trial comparing drug to chlorambucil in patients with progressive disease (ASCO)

ILEX
Oncology
Inc.
(ILXO)

ILX-651

Next-generation synthetic pentapeptide analogue of dolastatin

Hormone- refractory cancer

Began Phase II trial in 40 patients whose disease has progressed after Taxotere treatment (6/17)

ImClone
Systems
Inc.
(IMCL)

Erbitux (FDA-approved)

Cetuximab; antibody that blocks the epidermal growth factor receptor

Advanced head and neck cancer and other cancers

Phase III trial with high-dose radiation met endpoints of locoregional control and survival in head and neck cancer; presented data from four combination trials in colorectal cancer; two Phase II combination trials in non- small-cell lung cancer showed benefit vs. chemotherapy alone; two Merck KGaA-sponsored studies in advanced squamous- cell carcinoma of the head and neck had a disease control rate of 45.6% and 69.8% (ASCO)

ImClone
Systems
Inc.
(IMCL)

IMC-BEC2

Cancer vaccine; anti- idiotypic monoclonal antibody that mimics GD3

Small-cell lung cancer

Two-year Phase III trial did not demonstrate a survival benefit (ASCO)

Immunomedics
Inc.
(IMMU)

CEA-Cide (labetuzmab)

Humanized antibody against carcinoembryonic antigen, labeled with 90-yttrium

Advanced colorectal and pancreatic cancers

Phase I studies in each cancer showed tumor targeting, accept- able normal organ radiation doses and a maximum dose (6/21)

Immunomedics
Inc.
(IMMU)

Epratuzumab

Humanized anti-CD22 monoclonal antibody

Aggressive non- Hodgkin's lymphoma

Pilot study with Rituxan and CHOP regimen and Phase II with Rituxan showed promising activity; also reported on Phase I/II trial on radiolabeled form of drug (ASCO)

Inex
Pharmaceuticals
Corp.
(Canada; TSE:IEX)
and Enzon Pharmaceuticals
Inc.
(ENZN)

Onco TCS

Vincristine encapsulated in Inex's TCS (liposomal) drug delivery technology

Aggressive non- Hodgkin's lymphoma

Follow-up Phase II data showed a complete response rate of 91% (62 of 68) in first-line treatment as part of chemotherapy regimen (ASCO)

Introgen
Therapeutics
Inc.
(INGN)

INGN 241

Agent containing the tumor- suppressor gene Mda-7/IL-24

Solid tumors

Final data from Phase I trial demonstrated clinical and biological activity (6/7)

Introgen
Therapeutics
Inc.
(INGN)

Advexin

Adenoviral vector containing the p53 tumor-suppressor gene

Cancers

Presented data from 445 patients in 14 trials showing safety, tolerability and activity as a single agent and in combination trials (6/3 and ASCO)

Keryx Bio- pharmaceuticals
Inc.
(KERX)

KRX-0401 (perifosine)

Oral AKT inhibitor

Non-small-cell lung cancer

Began Phase II trial to test safety and efficacy of single- gent treatment in progressed disease (6/10)

Kosan
Biosciences
Inc.
(KOSN)

KOS-862

Epothilone D

Colorectal and prostate cancers

Roche and Kosan stopped development in colorectal cancer due to toxicities seen in Phase II trial; they plan a Phase II trial in prostate cancer (6/22)

Kosan
Biosciences
Inc.
(KOSN)

17-AAG

17-allylamino-17-demeth- oxy-geldanamycin; inhibits heat-shock protein 90

Solid tumors

Presented data from four Phase I or II trials; drug was well tolerated (ASCO)

Kudos
Pharmaceuticals
Ltd.*
(UK) and
Novacea Inc.*

AQ4N

Hypoxic cell-activated antitumor therapy

Advanced esophageal carcinoma

Interim Phase I results showed AQ4N to be well tolerated with a favorable pharmacokinetic profile (ASCO)

Ligand
Pharmaceuticals
Inc.
(LGND)

Avinza (FDA-approved)

Extended-release morphine

Chronic pain in cancer patients

Long-term, open-label trial demonstrated pain control with acceptable tolerability (ASCO)

Ligand
Pharmaceuticals
Inc.
(LGND)

Targretin (FDA- approved)

Bexarotene capsules

Non-small-cell lung cancer

Phase II trial with chemotherapy regimen showed improved event-free survival vs. historical controls; other trials showed tolerability and some activity (ASCO)

Maxim
Pharmaceuticals
Inc.
(MAXM)

Ceplene

Histamine dihydrochloride in combination with interleukin-2

Metastatic melanoma

Published 36-month follow-up data from M01 Phase III trial demonstrated statistically significant survival improvement vs. IL-2 alone (6/4)

Medarex
Inc.
(MEDX)

MDX-070

Fully human antibody to prostate-specific membrane antigen

Prostate cancer

Began Phase II trial in up to 30 patients with hormone-refractory disease (6/23)

Medarex
Inc.
(MEDX)

MDX-010

Fully human antibody against human CTLA-4

Metastatic melanoma

Overall response rate in Phase II trial with dacarbazine was 17.1%, or six of 35 patients (ASCO)

MediciNova
Inc.*

MN-029

Vascular targeting agent

Solid tumors

Plans to begin Phase I trial testing safety and tolerability (6/24)

MedImmune
Inc.
(MEDI)

Ethyol (FDA- approved)

Amifostine; cytoprotective agent

Dry mouth in radiation therapy patients

Phase III trial in 303 head and neck cancer patients showed drug reduced dry mouth, and that two years after treatment patients still produced saliva (ASCO)

Merix Bioscience
Inc.
(MERX)

--

RNA-loaded autologous dendritic-cell vaccine

Kidney cancer

Began Phase I/II trial in newly diagnosed patients with metastatic disease (6/8)

MGI
Pharma
Inc.
(MOGN)

Aloxi (FDA-approved)

Palonosetron hydrochloride injection; a 5-HT3 receptor antagonist

Nausea in patients undergoing chemotherapy

Presented various postmarketing and other data showing benefit (ASCO); presented summary data from various trials showing positive efficacy and quality-of- life results (6/25)

MGI Pharma
Inc.
(MOGN)

Irofulven

Hydroxymethylacylfulvene; compound from acylfulvenes family

Solid tumors

Phase II data from trials in three cancers demonstrated antitumor activity alone and in combination regimens (ASCO)

Millennium Pharmaceuticals
Inc.
(MLNM)

MLN2704

Monoclonal antibody (MLN591) directed at PSA conjugated to DM1

Hormone- refractory prostate cancer

Phase I trial in metastatic disease showed it was well tolerated and produced antitumor activity (ASCO)

Millennium Pharmaceuticals
Inc.
(MLNM)

Velcade (FDA-approved)

Bortezomib; proteasome inhibitor

Relapsed multiple myeloma and non-small- ell lung cancer

Phase III confirmatory trial showed statistically significant benefits in survival and time to disease progression vs. high- dose dexamethasone; data were presented from two investigator- sponsored trials; also presented promising Phase II data in non- small-cell lung cancer (ASCO)

NeoPharm
Inc.
(NEOL)

LEP-ETU

Liposomal formulation of paclitaxel

Advanced cancers

Phase I trial provided preliminary evidence of improved safety and tolerability (ASCO)

NeoPharm
Inc.
(NEOL)

LE-SN38

Liposomal formulation of the active metabolite of irinotecan

Advanced cancers

Patients were safely treated in a Phase I trial that used pharmaco- genomics in dosing (ASCO)

NeoRx
Corp.
(NERX)

Skeletal Targeted Radiotherapy

Bone-targeting molecule DOTMP with radioactive substance holmium-166

Multiple myeloma

Phase II dosimetry trial showed positive trends in both patient response and safety (ASCO)

OncoGenex Technologies Inc.* (Canada) and Isis Pharmaceuticals Inc. (ISIS)

OGX-011

Second-generation anti- sense agent designed to inhibit the production of clusterin

Prostate cancer

Phase I trial showed drug was well tolerated, achieved concentration in target tissue and produced a 91% dose-dependent down-regulation of clusterin (ASCO)

Onyx Pharmaceuticals Inc. (ONXX) and Bayer Pharmaceuticals Corp.

BAY 43-9006

RAF kinase and VEGF inhibitor

Advanced renal- cell carcinoma and malignant melanoma

Phase II single-agent trial showed responses in 89 of 106 patients who were assessed at 12 weeks; also presented encouraging Phase l/II data on combination therapy in advanced malignant melanoma (ASCO)

OSI
Pharmaceuticals
Inc.
(OSIP)

Aptosyn (exisulind)

Small molecule that augments apoptosis in precancerous cells

Advanced non- small-cell lung cancer

Phase III trial in combination with Taxotere did not meet primary endpoint of improving overall survival; also missed secondary endpoints (6/11)

Pharmacyclics
Inc.
(PCYC)

Xcytrin

Motexafin gadolinium; small molecule from the texaphyrin class designed to induce apoptosis

Non-Hodgkin's lymphoma

Began Phase II trial to study efficacy and safety in 35 to 40 patients with low-grade NHL who relapsed after Rituxan therapy (6/16)

Pharmacyclics Inc. (PCYC)

Xcytrin

Motexafin gadolinium; small molecule from the texaphyrin class designed to induce apoptosis

Advanced refractory tumors

Preliminary Phase I data of drug and Taxotere showed four of seven patients achieved a partial response (ASCO)

PharmaMar
SA*
(Spain)

Aplidin

Antitumor agent derived from the marine tunicate Aplidium albicans

Cancers

Gained approval to begin Phase II trials in the U.S. in multiple myeloma and prostate cancer (6/22)

PharmaMar
SA*
(Spain)

Kahalalide F

Peptides isolated from the Hawaiian mollusk, Elysia rufescens

Advanced prostate cancer

Phase I trial of the product demonstrated safety (ASCO)

PharmaMar
SA*
(Spain)

Yondelis

Trabectedin; ET-743; derived from the sea squirt Ecteinascidia turbinata

Various cancers

Data showed activity in sarcomas, tolerability and activity in refractory ovarian cancer, and activity in recurrent endometrial carcinoma (ASCO)

Point
Therapeutics
Inc.
(POTP)

Talabostat (PT-100)

Small molecule designed to stimulate proliferation of hematopoietic progenitor cells

Metastatic melanoma and chronic lymphocytic leukemia

Began Phase II trial in up to 54 melanoma patients in combination with cisplatin (6/17); began Phase II trial with Rituxan in up to 54 CLL patients (6/22); began Phase II single-agent trial in advanced melanoma (6/30)

Point
Therapeutics
Inc.
(POTP)

Talabostat (PT-100)

Small molecule designed to stimulate proliferation of hematopoietic progenitor cells

Solid tumors

Phase I data suggested drug can accelerate neutrophil recovery in patients receiving myelosuppressive chemotherapy (ASCO)

Procyon
BioPharma Inc.
(Canada; TSE:PBP)

PCK3145

Synthetic peptide analogue of prostate secretory protein

Metastatic prostate cancer

Final Phase IIa results in 16 pat- ients with hormone-refractory disease confirmed safety, tolerability and preliminary efficacy at all dose levels tested (ASCO)

Pro-Pharmaceuticals Inc. (AMEX:PRW)

Davanat

Carbohydrate compound designed for targeted delivery

Advanced solid tumors

Interim tolerability data from Phase I trial in combination with 5-FU were positive (6/23)

Regeneron
Inc.
(REGN)

VEGF Trap

Intravenous product designed to block vascular endothelial growth factor

Advanced solid tumors

Phase I trial showed it can bind VEGF in patients and was well tolerated (ASCO)

Seattle
Genetics
Inc.
(SGEN)

SGN-15

Antibody-drug conjugate that provides targeting to doxorubicin

Non-small-cell lung cancer

Phase II trial in 62 refractory patients showed improved survival with Taxotere vs. Taxotere alone, 7.3 months to 5.9 months (ASCO)

Sonus
Pharmaceutical
Inc.
(SNUS)

Tocosol Paclitaxel

Formulation of paclitaxel using Sonus' delivery system

Various cancers

Presented ongoing results from Phase IIa trials in three tumor types showing tolerability and encouraging efficacy data (ASCO)

Spectrum Pharmaceuticals
Inc.
(SPPI)

EOquin

Anticancer agent

Superficial bladder cancer

Additional data from single- gent Phase I trial demonstrated safety and complete response in eight of 10 patients (6/24)

Sunesis
Pharmaceuticals
Inc.*

SNS-595

Small-molecule cell- cycle modulator designed to induce apoptosis

Cancers

Began Phase I trial in patients with advanced disease to examine safety, tolerability, pharmacokinetics and dosing (6/28)

SuperGen
Inc.
(SUPG)

Dacogen

Decitabine for injection

Myelodysplastic syndromes

Phase I trial with carboplatin in advanced solid tumors confirmed feasibility of the combination (ASCO)

SuperGen
Inc.
(SUPG)

Nipent (FDA- approved)

Pentostatin for injection

Leukemias and lymphomas

Presented data from three combination trials showing treatment was active, well tolerated and did not increase toxicity (ASCO)

Telik
Inc.
(TELK)

Telcyta

Small-molecule tumor- activated drug designed to induce apoptosis

Non-small-cell lung cancer

Began Phase II trial with carboplatin and paclitaxel in the front- line treatment of Stage IIIb or IV disease (6/30)

Telik
Inc.
(TELK)

Telcyta

Small-molecule tumor-activated drug designed to induce apoptosis

Ovarian and non-small-cell lung cancers

Presented results from three Phase II combination trials showing encouraging response rates in refractory patients (ASCO)

Therion Biologics Corp.*

Panvac-VF

Vaccine designed to stimulate the immune system to target and destroy cells expressing CEA and mucin-1

Metastatic pancreatic cancer

Began pivotal Phase III trial to test survival in 250 patients in whom gemcitabine is ineffective (6/21)

Therion Biologics Corp.*

Panvac-VF

Vaccine designed to stimulate the immune system to target and destroy cells expressing CEA and mucin-1

Advanced pancreatic cancer

Phase I trial showed survival of at least 5.3 months vs. an expected three months; additional safety data also were reported; and CEA-VF/ Tricom Phase I trial showed median survival of 7.9 months (ASCO)

Threshold Pharmaceuticals
Inc.*

Glufosamide

Isophosphoramide mustard linked to beta-D-glucose

Breast and colon cancers

Antitumor activity was seen in Phase II trials in both indications (ASCO)

Titan
Pharmaceuticals
Inc.
(AMEX:TTP)

Pivanex

Agent designed to inhibit histone deacetylases class of enzymes

Non-small-cell lung cancer

Discontinued Phase IIb study in combination with docetaxel after interim safety analysis found significant safety issues (6/21)

Transgene
SA
(France;
TRGNY)

MVA-Muc1- IL2 vaccine

Product using the MVA virus to carry and express two antigens found in HPV 16

Prostate and non-small-cell lung cancers

Vaccination produced increases in PSA doubling time in Phase II prostate cancer trial; seven of 18 NSCLC patients responded in Phase II trial (ASCO)

U.S. Oncology
Inc.*

Abraxane

Nanoparticle albumin-bound paclitaxel

Metastatic breast cancer

Trial showed a 15% overall response rate and tolerability in 106 patients (ASCO)

VasGene
Therapeutics Inc.*

Veglin

Antisense oligonucleotide that binds VEGF

Various cancers

Phase I trial showed the drug was safe and demonstrated clinical activity (ASCO)

Vical
Inc.
(VICL)

Allovectin-7

DNA plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and ß2 microglobulin

Metastatic melanoma

Phase II trial testing high doses in 127 refractory patients showed a response rate of 10.2%, as well as tolerability (ASCO)

Vion
Pharmaceuticals
Inc.
(VION)

Cloretazine (VNP40101M)

Sulfonyl hydrazine DNA alkylating agent

Leukemia

Phase I trial in combination with cytosine arabinoside data in 34 patients produced positive results (ASCO)

Vion
Pharmaceuticals
Inc.
(VION)

Cloretazine (VNP40101M)

Sulfonyl hydrazine DNA alkylating agent

Cancer

Initial Phase I data on 23 patients showed it was well tolerated and showed effect, but did not produce clinical responses (ASCO)

Vion
Pharmaceuticals
Inc.
(VION)

Cloretazine (VNP40101M)

Sulfonyl hydrazine DNA alkylating agent

Brain cancer

Began Phase II trial to assess the activity and toxicity in adult patients with recurrent gliomas (6/1)

Wilex
AG*
(Germany)

Rencarex (WX-G250)

Chimeric monoclonal IgG1 antibody that binds to the MN cell-surface antigen

Renal-cell carcinoma

Began pivotal Phase III ARISER trial in 612 patients in Europe and the U.S. as an adjuvant therapy in clear-cell RCC (6/15)

Xanthus
Life Sicences*

Symadex (C-1311)

Next-generation product based on mitoxantrone, from the imidazoacri-dinone family

Advanced solid tumors

Began Phase I trial in 15-20 patients to assess pharmacokinetics and dosing (6/15)

Xcyte
Therapies
Inc.
(XCYT)

Xcellerated T Cells

T cells from patient stimulated to carry out immune functions

Various cancers

Positive data were seen in Phase I/II trials in chronic lymphocytic leukemia, multiple myeloma and prostate cancer (ASCO)

Xenova
Group
plc
(UK; XNVA)

Tariquidar

P-glycoprotein membrane inhibitor

Solid tumors in children

NCI investigators presented Phase I data indicating the drug was well tolerated in children (ASCO)

CARDIOVASCULAR

Archemix
Corp.*
and
Nuvelo
Inc.
(NUVO)

ARC183

Anti-thrombin aptamer

Anticoagulant

Filed IND for Phase I trial for potential use in coronary artery bypass graft surgery (6/30)

Cerus
Corp.
(CERS)

Intercept Blood System

Pathogen-inactivation system for red blood cells that uses the compound S-303

Blood transfusions

Independent analysis of Phase III trial showed no statistically significant differences in respiratory adverse events between test and control groups (6/16)

Corgentech
Inc.
(CGTK)

E2F Decoy (edifoligide)

Oligonucleotide designed to inactivate the cell-cycle transcription factor E2F

Coronary artery bypass graft failure

Monitors in final review said Phase III PREVENT IV CABG trial could continue as planned (6/24)

CoTherix
Inc.*

Ventavis

Iiloprost inhalation solution; prostacyclin analogue

Pulmonary arterial hypertension

Began Phase II STEP trial in combination with Tracleer in 60 patients (6/15)

Dyax Corp.
(DYAX) and
Genzyme
Corp.
(GENZ)

DX-88

Recombinant small protein designed to inhibit human plasma kallikrein

Hereditary angioedema

Phase II EDEMA1 trial met primary endpoint of improving symptoms of acute attacks of HAE within four hours of treatment (6/14)

Emisphere
Technologies
Inc.
(EMIS)

--

Oral heparin formulated with Eligen delivery technology

Thrombolytic agent

Began trial to select appropriate oral dosing for late-stage clinical trials (6/16)

Endovasc
Inc.
(OTC
BB:EVSC)

Liprostin

Liposome-encapsulated form of prostaglandin E1

Peripheral vascular disease

Data from first 28 patients in Phase II trial showed improvements in endpoints related to walking distance (6/9)

Millennium Pharmaceuticals
Inc.
(MLNM) and Schering-Plough
Corp.

Integrilin (FDA- approved)

Eptifibide; glycoprotein IIb-IIIa inhibitor

Acute coronary syndrome

Began Phase IIIb EARLY ACS trial in up to 10,500 patients worldwide to assess the benefit in high-risk patients experiencing non-ST-segment elevation ACS (6/1)

Nabi Bio- pharmaceuticals
Inc.
(NABI)

PhosLo

Calcium acetate

Control of blood phosphorus in end-stage renal disease

Began Phase IV PRECISE trial to evaluate drug with the statin Lipitor in about 150 patients (6/10)

Nuvelo
Inc.
(NUVO)

Alfimeprase

Modified fibrolase delivered via catheter; thrombolytic agent

Acute peripheral arterial occlusion

Phase II trial showed drug re- stored blood flow in four hours or less, as well as a dose response (6/28)

Nuvelo
Inc.
(NUVO)

Alfimeprase

Modified fibrolase delivered via catheter; thrombolytic agent

Venous catheter occlusion

Monitors recommended Phase II trial continue in the two highest dose groups after looking at data from 48 patients (6/9)

Nuvelo
Inc.
(NUVO)

Alfimeprase

Modified fibrolase delivered via catheter; thrombolytic agent

Chronic peripheral arterial occlusion

Preliminary data from 87 patients in Phase II trial showed a clear ose response, as well as safety and tolerability (6/5)

Synthetic
Blood
International
Inc.
(OTC BB:SYBD)

Oxycyte

Perfluorocarbon-based blood substitute and therapeutic oxygen carrier

Blood substitute

Phase I safety trial supported move into Phase II development (6/14)

CENTRAL NERVOUS SYSTEM

Acadia
Pharmaceuticals
Inc.
(ACAD)

ACP-103

Small-molecule, 5-HT2A inverse agonist

Parkinson's disease

Phase Ib/IIa trial in 12 patients demonstrated safety and tolerability (6/29)

Amgen
Inc.
(AMGN)

GDNF

Glial cell line-derived neurotrophic factor

Parkinson's disease

Phase II trial in 34 patients with advanced disease failed to meet primary endpoint of improving symptoms at six months (6/28)

Axonyx
Inc.
(AXYX)

Phenserine

Inhibitor of acetylcholin- esterase and beta-amyloid precursor protein

Alzheimer's disease

Began second Phase III trial to evaluate safety and efficacy of two doses in mild to moderate AD patients treated for six months (6/16)

Delex
Therapeutics
Inc.*
(Canada)

AeroLEF

Aerosolized liposome- encapsulated fentanyl

Pain following knee surgery

Preliminary Phase IIa results were called encouraging (6/9)

Guilford Pharmaceuticals
Inc.
(GLFD)

Aquavan injection

Water-soluble prodrug of propofol

Sedation

Confirmatory Phase II trial in 64 colonoscopy patients showed rapid onset and recovery without serious adverse effects (6/17)

Orphan
Medical
Inc.

Xyrem (FDA- approved)

Sodium oxybate oral solution

Fibromyalgia

Began trial to evaluate drug for treating symptoms of fibromyalgia in 150 patients (6/30)

Orphan
Medical Inc.

Xyrem (FDA- approved)

Sodium oxybate oral solution

Excessive daytime sleepiness

Presented statistically significant results from 228-patient trial in EDS associated with narcolepsy (6/9)

Pain
Therapeutics
Inc.
(PTIE)

Remoxy

Capsule formulation of oxycodone, designed to be abuse-resistant

Pain

Head-to-head study vs. oxycodone in human volunteers showed Remoxy was significantly less abusable (6/29)

Repligen
Corp.
(RGEN)

RG2133

Prodrug of uridine, which acts on cell metabolism

Bipolar disorder and major depression

Phase I trial showed the drug appeared to be safe, did not induce mania, and provided early evidence of a clinical effect (6/10)

Rinat
Neuroscience
Corp.*

RI 624

Humanized monoclonal antibody that inhibits nerve growth factor

Pain

Began a Phase I trial to test safety (6/23)

Sepracor
Inc.
(SEPR)

Estorra

Eszopiclone tablets

Insomnia

Presented six posters describing positive results on sleep in elderly and non-elderly patients (6/8); new data from Phase III analysis howed improved sleep maintenance regardless of WASO levels (6/10)

Titan
Pharmaceuticals
Inc.
(AMEX:TTP)

Probuphine

Buprenorphine formulated with Titan's ProNeura delivery system

Opiate addiction

Presented data from 12-patient pilot trial showing maintenance of benefit after switch from buprenorphine therapy to Probuphine (6/3)

Vela
Pharmaceuticals
Inc.*

VPI-013

Combination 5-HT(1A) receptor agonist, serotonin reuptake inhibitor and sigma receptor agonist

Depression

Began trial to test efficacy and safety in patients with major depressive disorder (6/29)

Xenova Group
plc
(UK; XNVA)

TA-CD

Vaccine designed to produce anti-cocaine antibodies

Cocaine addiction

The vaccine showed promise in a number of areas in Phase II trials involving 22 cocaine users (6/14)

DIABETES

Amylin
Pharmaceuticals
Inc.
(AMLN) and
Eli Lilly and Co.

Exenatide

Incretin mimetic; synthetic exendin-4

Type II diabetes

Data from two of three pivotal studies showed significant lowering of blood sugar levels in patients unable to lower glucose levels with common oral regimens (6/5)

BioStratum Inc.*

Pyridorin

Small molecule designed to inhibit formation of glycation end-products

Diabetic kidney disease

Phase IIa and IIb trials showed positive effects on creatinine levels and demonstrated safety and tolerability (6/7)

Emisphere Technologies
Inc.
(EMIS)

--

Oral insulin tablet that uses company's Eligen technology

Type II diabetes

13-patient trial showed a positive impact on glycemic control and tolerability (6/7)

Generex
Biotechnology Corp.
(Canada; GNBT)

Oralin

Oral insulin spray formulation

Type I diabetes

Presented positive pharmac-kinetic data and results vs. s.c. regular insulin in two trials (6/8)

Nektar
Therapeutics
(NKTR)

Exubera

Product that uses Nektar's inhaler and powdered insulin formulation

Type II diabetes

Pfizer Inc. and Aventis SA presented two-year open-label data showing sustained glycemic control and pulmonary function (6/7)

INFECTION

Cubist
Pharmaceuticals
Inc.
(CBST)

Cubicin (FDA- approved)

Daptomycin for injection

Complicated skin and skin- tructure infections

Published data from two pivotal Phase III trials showed statistical significance for safety and efficacy vs. comparator agent (6/16)

Dynavax
Technologies
Corp.
(DVAX)

AIC

Anti-allergy immunotherapy

Ragweed allergy

Phase I trial in 24 children demonstrated tolerability (6/24)

Indevus Pharmaceuticals
Inc.
(IDEV)

Aminocandin

Fungicidal agent from the echinocandins class

Fungal infections

Phase I trial showed drug was well tolerated in healthy volunteers and demonstrated prolonged antifungal activity (6/9)

Inhibitex
Inc.
(INHX)

Veronate

Antibody-based immune globulin

S. aureus infections in infants

Began pivotal Phase III trial to prevent hospital-associated infections in very-low-birth-weight infants (6/30)

InterMune
Inc.
(ITMN)

Infergen (FDA-approved)

Interferon alfacon-1

Hepatitis C

Began Phase III DIRECT trial to evaluate the safety and efficacy with ribavirin in 510 HCV non-responder patients (6/15)

IntraBiotics Pharmaceuticals
Inc.
(IBPI)

Iseganan

Antimicobial peptide; a protegrin

Ventilator- associated pneumonia

Stopped pivotal study after monitors saw increased mortality and disease in the drug group (6/23)

Nabi Bio- pharmaceuticals
(NABI)

StaphVAX

Staphylococcus aureus polysaccharide conjugate vaccine

S. aureus infections

Began additional studies of the vaccine to include cardiovascular and orthopedic surgery patients (6/22)

Panacos Pharmaceuticals
Inc.*

PA-457

Small-molecule drug from new class named maturation inhibitors

HIV

Phase I trial in healthy volunteers showed tolerability; company began multiple-dose safety trial (6/1)

Peninsula Pharmaceuticals Inc.*

Doripenem (S-4661)

Agent from the carbapenem class of beta-lactam antibiotics

Hospital- acquired pneumonia

Began pivotal Phase III trial comparing safety and efficacy to piperacillin/tazobactam; it is the fifth pivotal trial of the drug (6/10)

Spherics Inc.*

Spherazole

Oral itraconazole that incorporates Spherics' bioadhesive technology

Fungal infections

Began Phase I trial to evaluate the potential of the delivery technology (6/14)

Valeant Pharmaceuticals
Inc.
(NYSE:VRX)

Viramidine

Oral nucleoside analogue

Hepatitis C

Began second of two Phase III trials in conjunction with a pegylated interferon; the VISER2 trial will enroll about 1,000 patients (6/14)

Vertex
Pharmaceuticals
Inc.
(VRTX)

VX-950

Oral protease inhibitor

Hepatitis C

Began Phase I trial to assess safety, tolerability and pharmacokinetics of escalating single doses in healthy volunteers (6/8)

Vical Inc.
(VICL)

--

Plasmid DNA-based anthrax vaccine

Anthrax infection

Beginning Phase I trial, which is being supported by the National Institute of Allergy and Infectious Diseases (6/1)

ViroPharma
Inc.
(VPHM)

HCV-086

Antiviral compound from new chemical series

Hepatitis C

Began trial in 96 patients to eval- uate antiviral activity, safety and pharmacokinetics of ascending doses (6/8)

MISCELLANEOUS

Advanced
Magnetics Inc.
(AMEX:AVM)

Ferumoxytol

Intravenously administered, bioavailable iron

Iron replacement

Began a Phase III trial in anemic chronic kidney disease patients who are on hemodialysis (6/16)

BioMarin
Pharmaceutical
Inc.
(BMRN)

Aryplase

Enzyme-replacement therapy

Mucopoly- saccharidosis-VI

Phase III trial in 39 patients demonstrated a statistically significant improvment in endurance, the primary endpoint, and that it was well tolerated in general (6/3)

BioSante Pharmaceuticals
Inc.
(AMEX:BPA)

LibiGel

Transdermal testosterone gel

Female sexual dysfunction

Phase II trial in 46 patients demonstrated no safety concerns; efficacy data were being analyzed (6/23)

CollaGenex Pharmaceuticals
Inc.
(CGPI)

Col-101 (Periostat MR)

Modified-release formulation of doxycycline

Rosacea

Began two Phase III trials with up to 264 patients each to assess benefit over 16 treatment weeks (6/15)

Genaera Corp.
(GENR)

Squalamine

Anti-angiogenesis agent; VEGF inhibitor

Wet age-related macular degeneration

Began a second Phase II trial to assess safety and efficacy over two years in 100 patients (6/16)

Inflazyme Pharmaceuticals
Ltd.
(Canada; TSE:IZP)

IPL512,602

Leukocyte-selective anti-inflammatory agent

Asthma

Phase IIa trial failed to meet the primary endpoint vs. placebo in improving FEV1; no more development was expected (6/18)

Inspire Pharmaceuticals
Inc.
(ISPH)

Diquafosol tetrasodium

Ophthalmic solution

Dry eye

Began Phase III trial in 500 patients, as called for following FDA approval letter in December 2003 (6/2)

Nastech Pharmaceutical
Co. Inc.
(NSTK)

PYY3-36 Nasal Spray

High-affinity Y2 receptor agonist

Obesity

Phase Ic study showed the product reduced caloric intake, led to weight loss and was safe and well tolerated (6/29)

NitroMed Inc. (NTMD) and Merck & Co. Inc.

--

Nitric oxide-enhancing COX-2 inhibitor

Pain, inflammation and other conditions

Merck moved the product into Phase II testing (6/22)

Nymox Pharmaceuticals Corp. (NYMX)

NX-1207

Investigational drug for BPH

Benign prostatic hyperplasia

Phase I/II trial in 20 men showed improved symptom scores and shrinkage in prostate size (6/24)

Palatin Technologies Inc. (AMEX:PTN)

PT-141

Intranasally delivered melanocortin agonist

Erectile dysfunction

Trial showed co-administration of PT-141 and Viagra was more efficacious than Viagra alone (6/8)

Serono SA (Switzerland; NYSE:SRA)

Serostim (FDA- approved)

Somatropin for injection

HIV-associated adipose redistribution syndrome

Began trial in 300 patients to assess benefit in reducing excess visceral fat accumulation (6/1)

Targeted Genetics Corp. (TGEN)

tgAAVCF

Gene therapy that uses an adeno-associated virus vector to deliver the CFTR gene directly into the lungs

Cystic fibrosis

Monitors of a Phase IIb trial recommended the trial continue as planned; the trial includes 100 patients (6/23)

Tercica Inc.
(TRCA)

--

Recombinant human insulin- like growth factor-1

Short stature caused by IGF deficiency

Phase III trial in 65 children demonstrated a statistically significant increase in growth rate, the primary endpoint, and an acceptable safety profile (6/16)


Notes:

* Privately held

ASCO = Data reported at American Society of Clinical Oncology meeting, held June 5-8 in New Orleans.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; CSE = Copenhagen Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange.

No Comments